Co-opting expression

Most if not all oncolytic virus companies are developing their viruses in combination with checkpoint inhibitors with the expectation that patient-specific neoantigens released by the viruses can "prime" immune responses to checkpoint therapy.

New preclinical data from Transgene S.A. support the feasibility of using oncolytic viruses to deliver checkpoint agents and hint that the approach could match the efficacy and improve the safety of co-administering the agents separately...